Background: There is some evidence that suggests a beneficial effect of calcium intake on serum lipid profile. The objective of this study was to determine the effect of 1000 mg calcium supplementation for 30 days on serum lipid profile in overweight or obese women. Methods: A double-blind, randomized clinical trial was conducted in 44 overweight or obese adult women (body mass index (BMI) X25 kg m À2 , age: 2576y) receiving 1000 mg elemental calcium daily (n ¼ 24) or placebo (n ¼ 20). Serum lipids, lipoproteins and apolipoproteins including triglyceride, total cholesterol, HDL cholesterol (HDLc), LDLc, VLDLc, ApoA-I and ApoB were obtained at baseline and after intervention. Dietary calcium and energy intake were estimated using 24 h dietary recall for 3 days. Statistical analyses were performed using SPSS software. Results: No significant differences were observed in dietary, anthropometric and serum variables between groups at baseline. Although serum total, LDL cholesterol and triglycerides tended to increase in both groups, total cholesterol elevation was significant only in placebo group (P ¼ 0.01). Triglyceride and VLDLc increased significantly only in the calcium group (P ¼ 0.03). LDLc elevation was significant in both groups (Po0.05). HDLc decreased significantly in both groups (Po0.01). Apolipoproteins did not change significantly in any group. No significant differences were observed in serum variables between groups after intervention. Conclusions: No considerable beneficial effect due to short-term calcium supplementation in overweight or obese women's lipid profile was observed. 
Introduction
The prevalence of obesity is rising to epidemic proportions around the world at an alarming rate. The rise in obesity is not restricted to more developed countries. The limited data available indicate that the prevalence of obesity in Middle Eastern countries is high, particularly in women who, in general, appear to have a higher prevalence of obesity than women in most western countries (IOTF, 2005) . As obesity is an important risk factor for hyperlipidemia (Krummel, 2004) ; therefore finding a way to assess lipid profile in such a high-risk group is of interest. There is some evidence that suggests a probable beneficial effect of calcium supplementation on circulating lipid concentration or at least on one item of lipoproteins (Bell et al., 1992; Denke et al., 1993; Entezari et al., 2001; Shahkhalili et al., 2001; Reid et al., 2002) . However, the results are not consistent. Some studies reported no significant effects from high calcium intake on lipid profile (Karanja et al., 1987; Bostick et al., 2000) . In most of the published papers, the changes in apolipoproteins have not been investigated. The mechanistic basis for changes in lipid profile has not been fully elucidated, but a hypothesis has been developed that a high concentration of calcium in the diet can promote the formation of indigestible calcium soaps in the gastrointestinal tract and thus inhibit the absorption of dietary fatty acids, including saturated ones (Denke et al., 1993; Welberg et al., 1994) .
On the basis of The National Comprehensive Study on Household Food Consumption Pattern and Nutritional Status IR IRAN, 2001 IRAN, -2003 , the mean per capita intake and requirement of calcium in Iran are 594 and 1036 mg/day, respectively (Kalantari et al., 2005) . This means that, according to the WHO/FAO recommendations, the average intake of calcium in Iran is approximately below 60% of the mean requirements (WHO/FAO, 2004 ) and it appears that even in cities that have the highest amount of calcium intake, no more than 70% of the requirements have been met. With this background, the use of calcium supplements could be justified in the obese population in whom hyperlipidemia is a prevalent phenomenon (Krummel, 2004) , and reports in this respect are scarce, especially in developing countries. On the basis of the recommendation of the World Health Organization (WHO) for the exertion of nutritional randomized controlled trials (RCTs) in various populations (de-Onis et al., 1998) , we decided to perform a randomized double-blind clinical trial to determine the effects of shortterm calcium supplementation on serum lipids, lipoproteins and apolipoproteins in overweight or obese women.
Materials and methods
This double-blind randomized clinical trial was conducted on a group of overweight or obese women (body mass index (BMI) X25 kg m
À2
) without a recent history of any type of weight loss medications, age 418 years; premenopause women with no evidence of existing chronic diseases, pregnancy, lactation, oral contraceptive use and any recent medical or nutritional treatments. Subjects who had recent calcium supplement intake were excluded from the study, and volunteers who consumed less than 100 capsules of the prescribed 120 calcium supplements or placebos were also excluded.
From 150 volunteers who were screened for study eligibility, 53 subjects were selected, fully informed about the project and were randomly divided into supplement (n ¼ 26) or placebo (n ¼ 27) groups. During the study, nine subjects were excluded and 44 participants (24 subjects in the calcium supplement group and 20 subjects in the placebo group) completed the study. All participants were students of medicine or allied health. The majority of participants were single (486%) and only three subjects in each group were married. Subjects were assigned to receive 1000 mg/day calcium as four calcium carbonate capsules. For every participant who attended randomly in the calcium supplement group, another participant was enrolled in the placebo group and both groups attended the study in parallel for a period of 20 days. Each calcium carbonate capsule contained 250 mg of elemental calcium (625 mg calcium carbonate), and the placebo contained 625 mg lactose. The capsules were taken twice daily (two with lunch and two with dinner or any time during the day if they failed to meet the schedule) while they pursued their normal lifestyle. Quality control of ten capsules was randomly carried out. Mean calcium computation was measured by volumetric method and the results were 237.5 and 0.6 mg in the calcium supplement and placebo capsules, respectively.
Blood samples (10 ml) and anthropometric measurements were collected at baseline and at the end of intervention after a minimum of 12 h overnight fasting, not during the menstruation days (for omitting probable hormonal effects on weight and lipid profile). After taking 10 ml of fasting blood, the samples were centrifuged at 3000 rpm. Blood serum was separated from the cells and each sample was divided into two parts. One part was used for triglyceride (TG), total cholesterol and HDL cholesterol (HDLc) assays, and the remaining samples were frozen for later apolipoprotein measurements. Cholesterol and TG were determined using commercial kits (Pars Azmoon, Tehran, Iran) and Alcyon 3000 autoanalyzer from Abbott Company. The Friedwald equation (Friedwald et al., 1972) was used to estimate LDL and VLDL cholesterols. The Nephelometric method was used to measure apolipoprotein concentrations using German Diagnostic kits and the Italian manufactured Minineph machine.
Body weight and height were determined using 'Seca' scale and stadiometer, respectively. All anthropometric measurements were done according to WHO protocols (WHO, 1995) . BMI was calculated from weight divided by height squared (kg m -2 ).
Dietary calcium and energy intakes were estimated using mean of three 24 h recalls (2 working days and one weekend) during the second or third week of intervention. The Iranian food composition table was used for calculating the intakes (Sarkisian et al., 1980) . SPSS software (version 9) was used for statistical analyses. Comparisons between groups were made by using independent-sample t-test. Paired sample t-test was used for comparing variables (within each group) before and after intervention. All statistical tests were done in two tail format, and P-value o0.05 was the level of significance.
Written consents were signed by the volunteers. To our knowledge, there was no threat of side effects for the subjects from receiving calcium supplements or lactose in the dose used in this study. The present study was approved by the Committee of Ethics of Ahwaz Jondi-Shapour University of Medical Science.
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Results
The subject's age and baseline anthropometric characteristics of the study groups are presented in Table 1 . No significant differences were observed between the calcium supplement and the placebo group at this point. The dietary energy and calcium intake during intervention are shown in Table 2 . Also no significant differences were observed between the groups during intervention. As shown in Table 3 , the differences between before and after intervention values of each individual were calculated and the mean differences between each group compared by t-test. There were no significant differences in lipid profile between the groups. Although serum total, LDL cholesterol and TG tended to increase in both study groups, total cholesterol elevation was significant only in the placebo group (P ¼ 0.01). TG and VLDLc increased significantly only in the calcium group (P ¼ 0.03). LDLc elevation was significant in both groups (Po0.05). HDLc decreased significantly in both groups (Po0.01). Apolipoproteins did not change significantly in the study groups. No significant differences were observed in serum variables between the groups after intervention.
Discussion
The results of this study showed that calcium supplementation has no considerable favorable effects on lipid profile in overweight or obese women; however, it might have a preventive effect on total cholesterol elevation.
The hypertriglyceridemic effect of calcium that we observed coincides with Entezari et al's. (2001) report and further findings of others, (Karanja et al., 1987; Bell et al., 1992) although the observed elevation in TG was not significant. However, our finding contraindicates the results reported by Shahkhalili et al. (2001) . The observed hypertriglyceridemia in our trial is of importance as it carries risk for CHD (Krummel, 2004) . Expectedly, this elevation in TG was paralleled with VLDLc elevation.
As significant elevation in total cholesterol concentration is seen only in the placebo group, it may be suggested that calcium supplementation exerted some sort of preventive effect on total cholesterol elevation. The non-significant change in total cholesterol in the calcium supplement group is in parallel with other findings (Karanja et al., 1987; Bell et al., 1992; Bostick et al., 2000; Entezari et al., 2001; Shahkhalili et al., 2001; Reid et al., 2002) except that reported by Denke et al. (1993) . Noting that this report suffers from weak points with regard to the number of participants, large amount of calcium supplemented and specific population investigated, more studies are still needed for a consistent conclusion.
The effect of calcium supplementation on HDLc is controversial (Karanja et al., 1987; Bell et al., 1992; Denke et al., 1993; Entezari et al., 2001; Shahkhalili et al., 2001; Reid et al., 2002; Ditscheid et al., 2005) . In our study, we observed a significant decrease in HDLc, which is in reverse with the TG change, a familiar phenomenon seen in many trials.
The reports concerning the effect of calcium supplementation on LDLc are also contradictory. Some report a decreasing effect (Bell et al., 1992; Denke et al., 1993; Shahkhalili et al., 2001; Ditscheid et al., 2005) , but this result was not observed in others (Karanja et al., 1987; Entezari et al., 2001; Reid et al., 2002) . Nevertheless, in our study, a significant increase in LDLc of both groups were observed; however, there were no significant differences between groups.
As shown in Table 3 , there was no significant change in apolipoproteins in any group. This result is consistent with Bell et al. (1992) and in contrast with what was reported by Entezari et al. (2001) . Although the increase in ApoB, in the calcium supplement group and placebo group was not Effect of calcium intake on serum lipid profile M Karandish et al significant and there were no significant differences between the groups, the increase of this parameter in the calcium supplement group was 4.7-fold larger than that of the placebo group (0.28/0.06). However, the LDLc of the placebo group increased 1.3 times more than that of the calcium group (17.5/13.2). As each LDL or VLDL molecule contains only one ApoB (Mayes, 2000) , the comparative elevation in ApoB and LDLc could suggest that LDLc increase in the calcium supplement group is due to the increase in the number of the particles. However, the increase of LDLc in the placebo group is attributed to the production of larger LDLs. This is not true, in the case of VLDLc because VLDLc changes are very similar in both groups. If this is true the production of small size LDL particles could expose those with calcium supplementation to higher risk for CHD (Schaefer, 2002; Grundy, 2006) . Although this suggestion is not approvable by our data, it is surely worthy of being investigated more thoroughly. The observed elevation in TG, total cholesterol, LDLc, VLDLc and decrease in HDLc concentrations could be caused by stressful situations experienced by the students during their final examination in the university (Goebel et al., 1998; Strauss-Blasche et al., 2003) . We started our intervention in April, which was almost 2 months before the students' final examination. Although this condition was the same for both groups, we suggested taking into account 'stress' as a probable confounding factor in further studies.
Most of the studies done in this field have assessed the short-term use of calcium supplementation on lipid profile (Karanja et al., 1987; Bell et al., 1992; Denke et al., 1993; Bostick et al., 2000; Entezari et al., 2001; Shahkhalili et al., 2001; Ditscheid et al., 2005) , and as far as we know Reid et al's. (2002) study is the only one that assessed the longterm effects of calcium supplementation on serum lipid concentrations. Therefore, further studies are needed to determine the effects of calcium supplementation on lipid profile. We conclude that supplementation with calcium in overweight or obese women does not have a considerable beneficial effect on lipid profile. Further simultaneous research on lipoproteins and apolipoproteins are needed for conclusive results. 
